Retinopathy of Prematurity
Focused reporting on ROP screening, diagnosis, and management. Includes updates on guidelines, technology, and neonatal care collaboration.
Three-year FIREFLEYE outcomes reported for aflibercept vs laser in ROP
Children treated with intravitreal aflibercept 0.4 mg for retinopathy of prematurity (ROP) maintained stable disease control and age-appropriate visual function through 3...
Study highlights link between obesity indicators and risk of retinopathy
Multiple obesity indicators are significantly associated with an increased risk of retinopathy, with the weight-adjusted waist index (WWI) showing the strongest predictive...
Declining trends in retinopathy of prematurity screening eligibility among U.S. infants
A recent national study analyzed trends in retinopathy of prematurity (ROP) screening eligibility among U.S. infants from 2003 to 2022, revealing a...
Standardized diagnosis of image-based diseases may be possible with federated learning
Federated learning, a method used to train machine learning models without sharing patient data, has the potential to standardize clinical diagnosis in retinopathy of prematurity (ROP), according to a study....
Adoptability of AI-based ROP screening may depend on commercial cost
Although it has the potential to be cost-effective compared with telemedicine and ophthalmoscopy, the ability to fully realize the benefits of artificial intelligence–based retinopathy of prematurity (ROP) screening in ophthalmology... ...
Low recurrence rate after intravitreal anti-VEGF injection in ROP
Treatment with intravitreal anti-VEGF for retinopathy of prematurity (ROP) is successful with a low rate of primary failure and recurrence, according to a study. In this retrospective study, the medical...
Can virtual screening for retinopathy of prematurity work in rural areas?
In rural and areas with limited resources, images with a noncontact fundus camera can be used to help detect treatable retinopathy of prematurity (ROP), according to a study. Screening criteria...
Lower dose bevacizumab effective for retinopathy of prematurity
Results from a retrospective review showed a 30-mcg dose of intravitreal bevacizumab is as effective as a 625-mcg dose for retinopathy of prematurity (ROP) treatment, with subsequent laser treatment rates...
Beyond Vision 2020: It’s back to the future for eye health
By Mark L. Dlugoss Senior Contributing Editor As eye care providers may recall, the World Health Organization (WHO) launched its Vision 2020 in 1999. This global initiative sought to eliminate...
There is nothing artificial about AI—it’s the real deal!
By Mark L. Dlugoss Senior Contributing Editor My first encounter with the concept of artificial intelligence (AI) was Stanley Kubrick’s science fiction film, “2001: A Space Odyssey.” When that film...
Intravitreal injection of either conbercept or ranibizumab effective in ROP
Intravitreal injection of conbercept or intravitreal injection of ranibizumab are both effective therapies for the treatment of retinopathy of prematurity (ROP), according to a study. In this prospective, randomized controlled trial... ...